quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·101d
PRRelease
Viking Therapeutics Inc. logo

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

VKTX· Viking Therapeutics Inc.
Health Care
Original source

Companies

  • VKTX
    Viking Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 26UpdateWolfe Research-
  • Oct 29UpdateCanaccord Genuity$106.00
  • Apr 29UpdateCantor Fitzgerald$104.00
  • Apr 8UpdateGoldman$30.00
  • Feb 13UpdateScotiabank$102.00
  • Feb 7UpdateCitigroup$38.00

Related

  • PR19h
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
  • PR1d
    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
  • PR13d
    Viking Therapeutics to Participate at Upcoming Investor Conferences
  • SEC22d
    SEC Form DEFA14A filed by Viking Therapeutics Inc.
  • SEC22d
    SEC Form DEF 14A filed by Viking Therapeutics Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.
  • ANALYST28d
    Wolfe Research initiated coverage on Viking Therapeutics
  • PR28d
    Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022